Janus Henderson Amends Travere Therapeutics Stake as of 12/31/23
Ticker: TVTX · Form: SC 13G/A · Filed: Feb 12, 2024 · CIK: 1438533
| Field | Detail |
|---|---|
| Company | Travere Therapeutics, Inc. (TVTX) |
| Form Type | SC 13G/A |
| Filed Date | Feb 12, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, equity-holdings
TL;DR
**Janus Henderson updated their Travere Therapeutics stake, watch for market reaction.**
AI Summary
Janus Henderson Group plc, a major investment advisor, filed an amended Schedule 13G/A on February 12, 2024, disclosing its ownership in Travere Therapeutics, Inc. common stock as of December 31, 2023. This amendment, the third for Janus Henderson, indicates a change in their beneficial ownership, which is important for investors as it signals a prominent institutional investor's updated position in the company. This matters to shareholders because significant changes in institutional holdings can influence stock price and reflect a major investor's confidence (or lack thereof) in Travere Therapeutics' future.
Why It Matters
This filing updates the public on Janus Henderson Group plc's stake in Travere Therapeutics, providing transparency on a significant institutional investor's position, which can impact market sentiment and trading decisions.
Risk Assessment
Risk Level: low — This is a routine amendment filing by an institutional investor, indicating a change in ownership rather than a new, high-risk event.
Analyst Insight
Investors should review the full SC 13G/A filing to understand the specific changes in Janus Henderson's ownership percentage and share count in Travere Therapeutics, as this could signal a shift in institutional confidence and potentially influence future stock performance.
Key Players & Entities
- Janus Henderson Group plc (company) — the reporting person and investment advisor
- Travere Therapeutics, Inc. (company) — the subject company whose common stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- February 12, 2024 (date) — the filing date of the SC 13G/A
FAQ
What type of filing is this and what does it signify?
This is an SC 13G/A filing, which is an amendment to a Schedule 13G. It signifies that Janus Henderson Group plc, an institutional investor, is updating its previously reported beneficial ownership of common stock in Travere Therapeutics, Inc. as of December 31, 2023.
Who is the reporting person in this filing?
The reporting person is Janus Henderson Group plc, identified by CIK 0001274173, an investment advice company based in London, UK.
Which company's securities are the subject of this filing?
The subject company is Travere Therapeutics, Inc., identified by CIK 0001438533, a pharmaceutical preparations company based in San Diego, CA.
What is the CUSIP number for the securities mentioned in the filing?
The CUSIP number for the Common Stock of Travere Therapeutics, Inc. is 89422G107, as stated on the cover page of the filing.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023, as specified in the filing.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on February 12, 2024 regarding Travere Therapeutics, Inc. (TVTX).